KALA News and Press, Kala Pharmaceuticals Inc. From 05/27/21

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is sche...

Oxford Finance announces the closing of a $125M senior secured term loan with Kala Pharmaceuticals ([[KALA]] -0.1%).Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophtha...

Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is schedu...

Kala Pharmaceuticals, Inc. (KALA) Q1 2021 Earnings Conference Call May 05, 2021, 08:00 ET Company Participants Niranjan Kameswaran - SVP, Strategy Mark Iwicki - Chairman, President & CEO Todd Bazemore - COO Mary Reumuth - CFO & Treasurer Conference Call Participants Andreas Argyrides ...

Kala Pharmaceuticals (KALA): Q1 GAAP EPS of -$0.49 misses by $0.01.Revenue of $3.27M (+205.6% Y/Y) misses by $0.23M.Press Release For further details see: Kala Pharmaceuticals EPS misses by $0.01, misses on revenue

-- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives -- -- New Credit Facility Provides up to $125M -- -- Cash Runway Projected for at Least Two Years -- ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Manageme...

Kala Pharmaceuticals’ Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021. The market uptake of Eysuvis has been good so far and will likely speed up further after more insurers come on...

Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just $6.1m in FY20. In October last year, Kala won approval for Eysuvis, a corticosteroid treatment for short-term symptoms of dry eye disease -...